Alzheimer’s disease: from pathogenesis to novel therapeutic approaches

Therapy ◽  
2009 ◽  
Vol 6 (2) ◽  
pp. 259-277 ◽  
Author(s):  
Elio Scarpini ◽  
Daniela Galimberti
2006 ◽  
Vol 2 ◽  
pp. S599-S599
Author(s):  
Olivier Boutaud ◽  
IrÃn̈e Zagol-Ikapitte ◽  
Venkataraman Amarnath ◽  
Valery Yermalitsky ◽  
Katrin I. Andreasson ◽  
...  

2008 ◽  
Vol 01 (09) ◽  
pp. 464-476 ◽  
Author(s):  
David B. Ascher ◽  
Gabriela A. N. Crespi ◽  
Hooi Ling Ng ◽  
Craig J. Morton ◽  
Michael W. Parker ◽  
...  

Neuron ◽  
2020 ◽  
Vol 108 (5) ◽  
pp. 801-821 ◽  
Author(s):  
Joseph W. Lewcock ◽  
Kai Schlepckow ◽  
Gilbert Di Paolo ◽  
Sabina Tahirovic ◽  
Kathryn M. Monroe ◽  
...  

2021 ◽  
Vol 22 (15) ◽  
pp. 8208
Author(s):  
Tien-Wei Yu ◽  
Hsien-Yuan Lane ◽  
Chieh-Hsin Lin

Alzheimer’s disease (AD) is a progressive neurodegenerative disease and accounts for most cases of dementia. The prevalence of AD has increased in the current rapidly aging society and contributes to a heavy burden on families and society. Despite the profound impact of AD, current treatments are unable to achieve satisfactory therapeutic effects or stop the progression of the disease. Finding novel treatments for AD has become urgent. In this paper, we reviewed novel therapeutic approaches in five categories: anti-amyloid therapy, anti-tau therapy, anti-neuroinflammatory therapy, neuroprotective agents including N-methyl-D-aspartate (NMDA) receptor modulators, and brain stimulation. The trend of therapeutic development is shifting from a single pathological target to a more complex mechanism, such as the neuroinflammatory and neurodegenerative processes. While drug repositioning may accelerate pharmacological development, non-pharmacological interventions, especially repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), also have the potential for clinical application. In the future, it is possible for physicians to choose appropriate interventions individually on the basis of precision medicine.


2020 ◽  
Vol 3 (2) ◽  
pp. 216-242 ◽  
Author(s):  
Mayuri Shukla ◽  
Areechun Sotthibundhu ◽  
Piyarat Govitrapong

The revelation of adult brain exhibiting neurogenesis has established that the brain possesses great plasticity and that neurons could be spawned in the neurogenic zones where hippocampal adult neurogenesis attributes to learning and memory processes. With strong implications in brain functional homeostasis, aging and cognition, various aspects of adult neurogenesis reveal exuberant mechanistic associations thereby further aiding in facilitating the therapeutic approaches regarding the development of neurodegenerative processes in Alzheimer’s Disease (AD). Impaired neurogenesis has been significantly evident in AD with compromised hippocampal function and cognitive deficits. Melatonin the pineal indolamine augments neurogenesis and has been linked to AD development as its levels are compromised with disease progression. Here, in this review, we discuss and appraise the mechanisms via which melatonin regulates neurogenesis in pathophysiological conditions which would unravel the molecular basis in such conditions and its role in endogenous brain repair. Also, its components as key regulators of neural stem and progenitor cell proliferation and differentiation in the embryonic and adult brain would aid in accentuating the therapeutic implications of this indoleamine in line of prevention and treatment of AD.   


Sign in / Sign up

Export Citation Format

Share Document